Skip to main content
. 2017 Dec 21;9(15):12479–12486. doi: 10.18632/oncotarget.23549

Figure 3.

Figure 3

Pooled HRs of PFS for patients with CR/PR after induction therapy (A) and those with SD (B) and pooled HRs of OS for patients with CR/PR after induction therapy (C) and those with SD (D) determined using direct meta-analysis. Abbreviations: Bev, Bevacizumab; HR, hazard ratio; PFS, progression-free survival; OS, overall survival; CR, complete response; PR, partial response; SD, stable disease.